Last reviewed · How we verify
Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in High-Risk Prostate Cancer Patients: A Multicenter, Single-Arm Clinical Study
Propranolol, a non-selective adrenergic beta-receptor blocker, is conventionally used to treat arrhythmias. However, recent studies have demonstrated its therapeutic efficacy in breast cancer, prostate cancer, neonatal hemangioma, and neonatal facial rhabdomyoma. Given the significant potential of neoadjuvant therapy in prostate cancer, we designed a multicenter, single-arm clinical study. This trial evaluates neoadjuvant propranolol combined with novel endocrine therapy and androgen deprivation therapy (ADT) in high-risk prostate cancer patients prior to radical prostatectomy, aiming to achieve superior curative outcomes.
Details
| Lead sponsor | Zhongda Hospital |
|---|---|
| Phase | NA |
| Status | NOT_YET_RECRUITING |
| Enrolment | 30 |
| Start date | Thu Jan 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Sep 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Prostate Cancer
Interventions
- Propranolol combined with novel endocrine therapy and androgen deprivation therapy
Countries
China